Skip Navigation


European Heart Journal Advance Access originally published online on March 17, 2009
European Heart Journal 2009 30(8):882-884; doi:10.1093/eurheartj/ehp105
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/8/882    most recent
ehp105v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Steinhubl, S. R.
Right arrow Articles by Berger, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steinhubl, S. R.
Right arrow Articles by Berger, P. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Aspirin following PCI: too much of a good thing?

Steven R. Steinhubl1,2,* and Peter B. Berger1

1 Geisinger Clinic, Danville, Pennsylvania, USA
2 The Medicines Company, 8058 Zurich-Flughafen, Switzerland

* Corresponding author. Tel: +41 44 810 0956, Fax: +41 43 813 3337, Email: steve.steinhubl@themedco.com

This editorial refers to ‘Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study’{dagger}, by S.S. Jolly et al., on page 900

The first 10% of the full text of this article appears below.

There is only one cardiovascular medication with a 4-fold difference in the ‘routine’ daily dose approved by regulatory bodies, recommended by guideline committees, and suggested by clinicians.1 That medication is acetylsalicylic acid (ASA), or aspirin. When considering any drug routinely used in the treatment of the patient with cardiovascular disease—statins, thienopyridines, angiotensin-converting enzyme (ACE) inhibitors, β-blockers—are there any in which a 4-fold difference in dose would not be expected to lead to significant differences in efficacy, safety, and tolerability? Yet with aspirin, the most widely used drug worldwide for cardiovascular disease prevention, the choice of dose is frequently based more on habit than on science. In fact, market research suggests that, among US cardiologists, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study
Sanjit S. Jolly, Janice Pogue, Kimberly Haladyn, Ron J.G. Peters, Keith A.A. Fox, Alvaro Avezum, Bernard J. Gersh, Hans Jurgen Rupprecht, Salim Yusuf, and Shamir R. Mehta
EHJ 2009 30: 900-907. [Abstract] [Full Text]